×
For best experience we recommend to activate Javascript in your browser.
UGGT1 antibody (C-Term)
This Rabbit Polyclonal antibody specifically detects UGGT1 in WB, IHC and ELISA. It exhibits reactivity toward Human.
Quick Overview for UGGT1 antibody (C-Term) (ABIN2382154)
Target
See all UGGT1 Antibodies
UGGT1
(UDP-Glucose Glycoprotein Glucosyltransferase 1 (UGGT1))
Reactivity
All reactivities for UGGT1 antibodies
Human
Host
All hosts for UGGT1 antibodies
Rabbit
Clonality
All clonalities for UGGT1 antibodies
Polyclonal
Conjugate
All conjugates for UGGT1 antibodies
This UGGT1 antibody is un-conjugated
Application
All applications for UGGT1 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), ELISA
Product Details anti-UGGT1 Antibody
(hide)
Binding Specificity
All epitopes for UGGT1 antibodies
AA 1225-1254, C-Term
Cross-Reactivity
Human
Cross-Reactivity (Details)
Calculated cross reactivity: Hu
Characteristics
UGCGL1, CT (UGGT1, GT, UGCGL1, UGGT, UGT1, UGTR, UDP-glucose:glycoprotein glucosyltransferase 1, UDP-Glc:glycoprotein glucosyltransferase, UDP-glucose ceramide glucosyltransferase-like 1)
Purification
Purified by Protein A affinity chromatography.
Immunogen
UGCGL1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1225-1254 amino acids from the C-terminal region of human UGCGL1.
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working conditions should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C
Target Details for UGGT1
(hide)
Target
UGGT1
(UDP-Glucose Glycoprotein Glucosyltransferase 1 (UGGT1))
Alternative Name
UGCGL1
NCBI Accession
NP_064505
UniProt
Q9NYU2
Pathways
Activation of Innate immune Response
Recently viewed
(hide)
Chat with us , powered by LiveChat